ResMed Upgraded to Outperform as Institutional Buying Accelerates

ResMed Inc. shares closed at USD 225.35 on Nasdaq on September 18, 2026, sitting approximately 6.7 percent below the current consensus analyst price target of USD 241.69. The primary catalyst for recent market attention is a research upgrade to Outperform issued on September 15, which raised the firm's price target to USD 262 from USD 244. This adjustment reflects confidence in the company's dominant position within the obstructive sleep apnea device sector, a segment that continues to drive long-term value creation for the business.

The upgrade coincides with visible new institutional accumulation, signaling that professional investors are positioning for continued growth. While the stock trades below both the new individual target and the broader consensus average, the combination of a higher price objective and fresh capital inflows underscores a shift in sentiment toward the company's fundamental strength and market leadership.

Fundamentals support the investment case

ResMed's recent financial performance provides a solid anchor for the upgrade. The company reported quarterly earnings of USD 2.95 per share, exceeding consensus expectations, on revenue of USD 1.46 billion. Top-line expansion was notable, with revenue growing 8.6 percent year over year in the reporting period. This mid-to-high single-digit growth rate indicates stable demand for the company's respiratory care products, supporting the argument for long-term value creation despite competitive pressures.

Shareholder returns have also increased, with the company raising its quarterly dividend to USD 0.66 per share in the latest period. This higher cash payout strengthens the income component of the investment thesis. For investors focused on total return, the mix of solid earnings beats, consistent revenue growth, and a rising dividend offers a balanced profile that contrasts with the higher-risk, higher-reward dynamics of pure growth stocks.

Institutional investors increase holdings

New capital has entered the shareholder base, with Nykredit A/S acquiring 338,702 ResMed shares during the second quarter. This position, valued at approximately USD 66 million, contributes to a broader trend of institutional ownership, which now stands at roughly 54.98 percent of the company's outstanding shares. The high level of professional ownership suggests that the stock is widely held by investors who are evaluating the business based on long-term operational metrics rather than short-term price fluctuations.

Despite this accumulation, the overall market sentiment remains cautious. The average analyst rating for ResMed is currently Hold, based on seven Buy ratings and nine Hold ratings. This split view highlights a divergence in how investors weigh the company's market leadership against rising competition and valuation risks. The recent upgrade to Outperform by one firm represents a bullish counterpoint to this broader caution, arguing that ResMed's product ecosystem and market position mitigate competitive threats.

Valuation and competitive risks persist

The stock's trading price of USD 225.35 leaves room for upside toward the consensus target of USD 241.69, implying potential gains of roughly 7.3 percent if the market reaches its average expectation. However, the Hold consensus rating indicates that many analysts remain balanced in their outlook. They acknowledge the company's earnings strength and dividend growth but maintain a cautious stance due to the competitive landscape in sleep apnea and respiratory care devices.

The upgrade cited in recent coverage explicitly addresses these competitive pressures, arguing that ResMed's leadership position supports continued growth. Nevertheless, the gap between the current share price and the highest individual target of USD 262 remains significant. Investors must weigh the firm's operational stability and shareholder returns against the risk that increased competition could compress margins or slow revenue growth in the coming quarters.